Abstract: Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive or inadequate cellular death.
Type:
Grant
Filed:
November 1, 2013
Date of Patent:
October 11, 2016
Assignees:
DANA-FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Inventors:
Loren D. Walensky, Stanley J. Korsmeyer, Gregory Verdine
Abstract: The present disclosure provides crystalline insulin-conjugates. The present disclosure also provides formulations, methods of treatment, methods of administering, and methods of making that encompass these crystalline insulin-conjugates.
Abstract: Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation, are described.
Abstract: Short biologically active tetrapeptides are disclosed that are comprised of the sequences GxxG and PxxP where G (glycine) and P (proline) are maintained and x is a variable amino acid. The peptides can be used singly or in combination to stimulate production of extracellular matrix proteins in skin. A rapid, low-cost method of producing heterogenous formulations of tetrapeptides is disclosed.
Type:
Grant
Filed:
November 3, 2014
Date of Patent:
September 20, 2016
Assignee:
HELIX BIOMEDIX INC.
Inventors:
Scott M. Harris, Timothy J. Falla, Lijuan Zhang
Abstract: The purpose of the present invention is to provide a novel method for producing cereulide and a derivative thereof; an intermediate for cereulide; and a novel cereulide derivative. A novel didepsipeptide, a novel tetradepsipeptide, a novel octadepsipeptide and a novel dodecadepsipeptide are prepared. A linear precursor of cereulide or a derivative thereof, which is composed of any one of the novel depsipeptides, is cyclized by forming an intramolecular amide bond.
Type:
Grant
Filed:
February 7, 2013
Date of Patent:
August 23, 2016
Assignees:
Stella Pharma Corporation, Osaka Prefecture University Public Corporation
Abstract: A molecular probe for use in detecting, monitoring, and/or imaging cancer cells and/or cancer cell metastasis, migration, dispersal, and/or invasion includes a targeting agent and a detectable moiety. The targeting agent specifically binds to and/or complexes with a proteolytically cleaved extracellular fragment of an immunoglobulin (Ig) superfamily cell adhesion molecule that is expressed by a cancer cell or another cell in the cancer cell microenvironment.
Abstract: Provided are methods of using gelsolin and active fragments thereof to neutralize, treat or prevent the pathogenic effects of lipoteichoic acid (LTA) toxins released from gram-positive bacteria, including massive activation of inflammatory response in a patient and the resulting lethal septic shock. The provided gelsolin binds to and neutralizes LTA from various bacteria, as well as eukaryotic acidic lysolipids adversely associated with bacterial sepsis and inflammation in the patient, with high affinity, thereby decreasing circulating LTA and the eukaryotic markers, and negating the deleterious biological effects of the gram-positive bacterial infection. Consequently, the provided gelsolin replacement therapy offers a method and compositions for the prevention of bacterial sepsis-induced mortality in the patient.
Type:
Grant
Filed:
March 28, 2006
Date of Patent:
August 9, 2016
Assignee:
The Trustees of the University of Pennsylvania
Abstract: A peptide having an amino acid sequence containing at least eight consecutive amino acids of the human lactoferrin protein or of the bovine lactoferrin protein. The peptide is suitable as a cell-penetrating peptide. A complex of the peptide and a cargo molecule non-covalently bound to the peptide. The cargo molecule may be a nucleic acid, an amino acid, a peptide, a protein, a carbohydrate, a lipid, or a small molecule. A method of penetrating or transfecting a cell using the complex.
Abstract: Methods and compositions for oral administration of melanocortin receptor agonist compounds are disclosed herein. Methods and compositions for oral administration of melanocortin receptor agonist compounds are provided for treatment of sexual dysfunction, including male sexual dysfunction and female sexual dysfunction. Methods and compositions for oral administration of melanocortin receptor agonist compounds are provided for treatment of metabolic syndrome, obesity and/or diabetes. In some embodiments, a pharmaceutical composition comprising a peptide-based melanocortin receptor agonist, a protease inhibitor, an absorption enhancer is administered orally.
Abstract: Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i.e., those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise occur between the acid of the compositions and other components of the composition. Use of these barrier layers and/or use of particulate coated acid is believed to promote a more simultaneous release of the components of the composition than is achieved by prior art acid-protection techniques, thus enhancing, and making more consistent, the bioavailability of the active peptide compounds.
Abstract: The present invention includes compound compositions and methods of making compounds that include an oligo-benzamide compound having at least two optionally substituted benzamides.
Type:
Grant
Filed:
October 28, 2013
Date of Patent:
July 19, 2016
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Abstract: The present invention encompasses a method for screening for a kokumi-imparting substance by using the calcium receptor activity as an index, a composition containing a kokumi-imparting substance obtained by the screening method, a method for producing food or drink imparted with kokumi, and food or drink imparted with kokumi.
Abstract: The invention relates to a biodegradable barrier network comprising at least two macromolecular substances, one being anionic and the other one cationic. The invention also relates to applicators and kits comprising components to be used to create said biodegradable barrier network. The invention also relates to the use of said applicator or kit in therapy, such as in medicine, veterinary medicine and horticulture.
Type:
Grant
Filed:
March 15, 2013
Date of Patent:
June 28, 2016
Assignee:
BioActive Polymers AB
Inventors:
Stig Bengmark, Kare Larsson, Bjorn Lindman, Roland Andersson
Abstract: A nutritional supplement composition for treating nutritional deficiencies caused by a medical condition in subjects is disclosed. The present application further discloses a method of using a nutritional supplements composition for treating a subject with complications resulting from sickle cell anemia. The method comprises administering to a subject an effective amount of the nutritional supplement.
Type:
Grant
Filed:
July 28, 2014
Date of Patent:
June 28, 2016
Assignee:
NUTRIGLOBAL, INC.
Inventors:
Jacqueline M. Hibbert, Jonathan K. Stiles, Kayellen Umeakunne, Hyacinth I. Hyacinth
Abstract: This invention concerns an in situ biodegradable hydrogel drug delivery system in which the components are assembled in a manner that provides a mechanism for the timed cleavage of a particular amide bond in a covalently linked active agent or of the hydrogel structure.
Type:
Grant
Filed:
November 20, 2009
Date of Patent:
May 24, 2016
Assignee:
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Inventors:
Patrick J. Sinko, Manjeet Deshmukh, Yashveer Singh, Simi Gunaseelan
Abstract: Conjugates of a Factor IX moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is polyethylene glycol) or a derivative thereof. Also provided (among other things) are compositions comprising the conjugates, methods of making the conjugates, and methods of administering to a patient compositions comprising the conjugates.
Type:
Grant
Filed:
November 8, 2013
Date of Patent:
May 24, 2016
Assignee:
Nektar Therapeutics
Inventors:
Mary J. Bossard, Gayle Stephenson Phillips
Abstract: The invention relates to polypeptides comprising an N-terminal portion and a C-terminal portion, wherein said N-terminal portion comprises the signature sequence QGP[P or L] and the amino acid sequence of said C-terminal portion is at least 70% identical to SEQ ID NO: 1, and uses thereof.
Abstract: A compound as represented by Formula (I) is provided, wherein groups are defined in the description. The compound is used as HCV protease inhibitor for treating HCV infection.
Type:
Grant
Filed:
December 5, 2012
Date of Patent:
April 26, 2016
Assignee:
GINKGO PHARAMA CO., LTD.
Inventors:
Ben Li, Li Chen, Peibing Zhai, Tao Jiang